Publications by authors named "D Guagnozzi"

Background: EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoate (ESO-101) is under investigation for the treatment of eosinophilic oesophagitis (EoE).

Aims: To evaluate the efficacy, safety and tolerability of ESO-101 in patients with active EoE.

View Article and Find Full Text PDF

Background: Eosinophilic esophagitis (EoE) predominantly affects males across all ages; however, little is known about sex differences for other aspects of EoE.

Objective: To investigate associations between sex and clinical presentation, endoscopic features, treatment choice and response in EoE patients in real-world practice.

Methods: Cross-sectional analysis of the multicenter EoE CONNECT registry.

View Article and Find Full Text PDF
Article Synopsis
  • Microscopic colitis (MC) and celiac disease (CD) are two chronic inflammatory conditions involving the colon and small bowel, respectively, with recent studies revealing a significant prevalence of both disorders coexisting in about 6% of refractory cases.
  • Both conditions display shared characteristics, including common risk factors, autoimmunity, and similar symptoms, while still maintaining some distinct differences.
  • More research is required to unravel the intricate mechanisms that link these diseases and clarify their epidemiological relationship.
View Article and Find Full Text PDF

This study compared short-term effectiveness of proton pump inhibitors (PPI), swallowed topical corticosteroids (STC), and dietary therapies in reversing clinical and histological features in pediatric patients with eosinophilic esophagitits (EoE). Determinants for treatment choice and PPI therapy effectiveness were also assessed.  A cross-sectional study analysis of patients under 18 years old recruited onto the multicenter EoE CONNECT registry was performed.

View Article and Find Full Text PDF
Article Synopsis
  • Swallowed topical corticosteroids (tC) are commonly used to treat eosinophilic esophagitis (EoE), but their effectiveness varies due to different formulations and doses.
  • A study analyzed data from the EoE CONNECT registry, focusing on clinical and histological remission rates based on various tC treatments used in real-world settings.
  • Results showed that higher doses (≥0.8 mg/day) improved remission rates, budesonide orodispersible tablets were the most effective, and factors like reduced symptom severity influenced treatment outcomes.
View Article and Find Full Text PDF